HC Wainwright Cuts Earnings Estimates for Krystal Biotech

Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) - HC Wainwright dropped their FY2026 earnings estimates for shares of Krystal Biotech in a report released on Monday, June 30th. HC Wainwright analyst J. Pantginis now anticipates that the company will post earnings of $6.07 per share for the year, down from their previous estimate of $6.30. HC Wainwright has a "Buy" rating and a $240.00 price objective on the stock. The consensus estimate for Krystal Biotech's current full-year earnings is $6.14 per share. HC Wainwright also issued estimates for Krystal Biotech's FY2027 earnings at $8.26 EPS and FY2028 earnings at $9.49 EPS.

Several other research analysts have also weighed in on KRYS. Chardan Capital reiterated a "buy" rating and set a $219.00 price objective on shares of Krystal Biotech in a report on Wednesday, May 7th. Citigroup dropped their price target on shares of Krystal Biotech from $215.00 to $155.00 and set a "neutral" rating for the company in a research report on Friday, May 16th. Finally, Guggenheim cut their price target on shares of Krystal Biotech from $195.00 to $189.00 and set a "buy" rating on the stock in a research note on Wednesday, May 7th. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Buy" and a consensus target price of $211.13.

Krystal Biotech Trading Up 1.2%

KRYS traded up $1.66 during midday trading on Tuesday, hitting $143.01. The company's stock had a trading volume of 168,281 shares, compared to its average volume of 287,155. The firm has a market cap of $4.13 billion, a P/E ratio of 34.38 and a beta of 0.67. The firm has a 50-day moving average price of $138.57 and a two-hundred day moving average price of $156.95. Krystal Biotech has a 52-week low of $122.80 and a 52-week high of $219.34.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The company reported $1.20 EPS for the quarter, missing analysts' consensus estimates of $1.38 by ($0.18). Krystal Biotech had a net margin of 37.17% and a return on equity of 14.64%. The business had revenue of $88.18 million during the quarter, compared to analysts' expectations of $98.66 million.

Hedge Funds Weigh In On Krystal Biotech

A number of hedge funds have recently made changes to their positions in KRYS. US Bancorp DE raised its holdings in shares of Krystal Biotech by 8.7% during the 4th quarter. US Bancorp DE now owns 1,027 shares of the company's stock valued at $161,000 after buying an additional 82 shares during the period. Charles Schwab Investment Management Inc. raised its stake in shares of Krystal Biotech by 1.2% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 243,170 shares of the company's stock valued at $38,095,000 after purchasing an additional 2,954 shares during the period. Arizona State Retirement System lifted its position in shares of Krystal Biotech by 8.5% during the fourth quarter. Arizona State Retirement System now owns 6,242 shares of the company's stock worth $978,000 after purchasing an additional 487 shares in the last quarter. Raymond James Financial Inc. acquired a new position in shares of Krystal Biotech during the fourth quarter worth $15,989,000. Finally, AlphaQuest LLC boosted its stake in shares of Krystal Biotech by 116.0% in the fourth quarter. AlphaQuest LLC now owns 3,020 shares of the company's stock valued at $473,000 after purchasing an additional 1,622 shares during the period. Hedge funds and other institutional investors own 86.29% of the company's stock.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).